This is a grant opportunity offered by Pfizer and the Beijing Guangda Precision Medicine Research Center. It seeks proposals for quality improvement initiatives focused on enhancing the management of adolescent and adult patients with Atopic Dermatitis (AD) or Alopecia Areata (AA). The goal is to identify solutions and remove barriers to improve the quality of care and promote best practices.

Focus and Objectives

The primary focus is on projects that improve the quality of diagnosis, treatment, and long-term management of AD or AA in adolescent and adult patients. Projects should aim to standardize practices and address gaps in care within the Chinese healthcare system.

Quality improvement projects must include a plan for measuring impact and outcomes. All intervention types within a QI framework are in-scope for this RFP including technology-based solutions, education or training initiatives, coordination of care between multiple centers or specialties, workflow or algorithm of quality control implementations, innovative digital solutions.

Projects should encompass systematic actions that directly impact patient care, with measurable outcomes. Priority will be given to projects using diversified, composite, and high-impact solutions at the provincial or city level.

Eligibility Criteria

Eligible applicants include medical, dental, nursing, allied health, and pharmacy professional schools, healthcare institutions, professional organizations, and government agencies. Only organizations are eligible, not individuals or medical practice groups.

• The project lead must be an employee or contractor of the requesting organization.

• Collaborations within and between institutions are encouraged.

• The requesting organization must be legally able to receive funding directly from Pfizer Investment Co., Ltd.

The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI’s grant/research coordinator).

Funding Details and Timeline

Individual projects can request up to $115,000. The maximum project length is 1.5 years. The estimated total available budget related to this RFP is $695,000.

The submission deadline is July 30, 2025. Award notifications will be sent by September 29, 2025, and the anticipated project start date is January 2026.

Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver.

Project Requirements

The primary areas of interest are Atopic Dermatitis (AD) and Alopecia Areata (AA). The focus is on identifying and addressing practice needs, barriers, and gaps for standardizing diagnosis, treatment, and long-term management in adolescent and adult patients with moderate-to-severe AD or severe AA, to improve quality of care and best practice in provinces or cities in China.

Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Projects must encompass systematic and continuous actions that directly impact patient care, including measurable outcomes via methodologically rigorous methods. Healthcare-associated direct & indirect cost is also considerable.

Adherence to local regulations and healthcare quality management plan regarding AD and AA diagnosis, treatment and management is essential. Sustainability of the initiative must be discussed in the proposal. Proposals that describe how its programmatic intervention can be expanded to other settings or regions to improve patient health outcomes are encouraged.

Submission Process

Applications must be submitted via the online portal at www.cybergrants.com/pfizer/QI. First-time users need to create a password. Complete all required sections of the online application and upload your project proposal in the Full Proposal Submission field.

In the application, select "Yes" for "Competitive Grant?" and choose the appropriate Primary Area of Interest: Dermatology - Atopic Dermatitis – QI, or Dermatology - Alopecia Areata – QI. Then, select the Competitive Grant Program Name: 2025 I&I CN Improving AD and AA Quality of Care to Standardize Management.

For questions regarding the RFP, direct them in writing to the Grant Officer, Juan Liu (GMGChina@pfizer.com), with the subject line “2025 I&I CN Improving Atopic Dermatitis and Alopecia Areata Quality of Care to Standardize Management, May 30, 2025”. All applicants will be notified via email by the dates noted above.